Riskpilot← Back to searchSign inGet full accessVITROW AS
ASActiveOrg 915295320Eikveien 60A, 3122 TønsbergMedical specialists activities · NACE 8622Est. 20150 employees
Revenue 2025
NOK 0
EBITDA margin
—
-24% vs 2024
Equity ratio
-129.4%
Financial strength
Net profit 2025
NOK -11K
-24% vs 2024
| Revenue | NOK 0 | — |
| EBITDA | NOK -11K | -24% |
| Net profit | NOK -11K | -24% |
| Total assets | NOK 30K | -2% |
| Equity | NOK -39K | -41% |
| Employees | 0 | — |
Legal name
VITROW AS
Org number
915295320
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
28. april 2015
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Styrets leder alene.
Company purpose
Eie og forvalte datterselskap og verdipapirer, drive handel og tjenesteytende virksomhet samt hva hermed står i forbindelse. Selskapet kan ved aksjetegning eller på annen måte engasjere seg i andre foretak med samme formål.
Address
Eikveien 60A, 3122 Tønsberg
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −0 | −0 | −9 | −9 | −11 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −0 | −0 | −9 | −9 | −11 |
| Net financials | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | −0 | −0 | −9 | −9 | −11 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −0 | −0 | −9 | −9 | −11 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 32 | 31 | 31 | 30 | 30 |
| Equity | −9 | −9 | −18 | −28 | −39 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 41 | 41 | 49 | 58 | 69 |
| Total debt | 41 | 41 | 49 | 58 | 69 |
EBITDA margin
-1130500.0%
This company
15.8%
Market median
-7155163% vs market
20212025
Equity ratio
-129.4%
This company
38.2%
Market median
-439% vs market
20212025
Return on equity
-1130500.0%
This company
18.4%
Market median
-6144122% vs market
20212025
Net profit margin
-1130500.0%
This company
8.1%
Market median
-13956890% vs market
20212025
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20212025
Debt / equity
1.77×
This company
0.62×
Market median
-185% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2018 | |
| Chairman | 2018 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 5% | 5% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
VITROW AS 
ARTEMIS GYNEKOLOGISKE SENTER ASBoard members of VITROW AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Joakim Martin | Board of Directors | 0 companies |
| Anna Nilsen Martin | Chairman | 0 companies |